Photo of Sara I. Pai,  MD, PhD

Sara I. Pai, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital


sara.pai@mgh.harvard.edu

Sara I. Pai, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Surgery, Harvard Medical School
  • Associate Surgeon, Surgery, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Sara Pai is an Associate Professor at Harvard Medical School and the Massachusetts General Hospital. She graduated Summa Cum Laude from Dartmouth College with a major in Biochemistry and Molecular Biology. After graduating Dartmouth, she completed the MD/PhD program at Johns Hopkins University School of Medicine in which she obtained her PhD training in cancer immunology and vaccines. After completing her residency in Otolaryngology-Head and Neck Surgery at Johns Hopkins Hospital, she joined its faculty in 2007 where she led a therapeutic HPV vaccine clinical trial which was supported by the Head and Neck Cancer SPORE grant. In 2014, she joined the faculty in the Department of Surgery at the Massachusetts General Hospital. Her research interests focus on better understanding how human papillomavirus (HPV) can evade the immune system and strategies that can be applied to reactivate the host immune response against the virus through vaccines and immune modulatory drugs. She leads several HPV related investigator-initiated clinical immunotherapy trials and has a research laboratory that is supported by the National Institutes of Health (NIH) as well as industry. She serves on grant and strategic review panels at the NIH and international government sponsored programs in the UK, Hong Kong, and Portugal. She is on the editorial board of lead scientific journals as well as serves on the advisory boards for several pharmaceutical companies.

Publications

Powered by Harvard Catalyst
  • Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR, . Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 2017. PubMed
  • Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J, Pai SI, Sidransky D, Westra WH, William WN, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM, . Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck 2017. PubMed
  • Mattox A, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, Diefenbach TJ, Morris LG, Lin DT, Wirth LJ, Lefranc-Torres A, Ishida E, Chakravarty PD, Johnson L, Zeng Y, Chen H, Poznansky MC, Iyengar NM, Pai SI. PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4+ TILs in the presence of PD-L1+ TAMs. Cancer Res 2017. PubMed
  • Pai SI, Faquin WC. Programmed cell death ligand 1 as a biomarker in head and neck cancer. Cancer 2017; 125:529-533. PubMed
  • Walline HM, Carey TE, Goudsmit CM, Bellile EL, D'Souza G, Peterson LA, McHugh JB, Pai SI, Lee JJ, Shin DM, Ferris RL, . High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 2016; 15:179-188. PubMed
  • Osho AA, Azzoli CJ, Pai S, Mino-Kenudson M, Faquin WC, Huynh TG, Lanuti M, Mathisen DJ, Muniappan A. Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. Ann Thorac Surg 2017; 103:e123-e125. PubMed
  • Pai SI, Zandberg DP, Strome SE. The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncol 2016; 61:152-8. PubMed
  • Brotherton JM, Jit M, Gravitt PE, Brisson M, Kreimer AR, Pai SI, Fakhry C, Monsonego J, Franceschi S. Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. Int. J. Cancer 2016; 139:510-7. PubMed
  • Peng S, Mattox A, Best SR, Barbu AM, Burns JA, Akpeng B, Jeang J, Yang B, Ishida E, Hung CF, Wu TC, Pai SI. Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes. Cancer Immunol Immunother 2016; 65:261-71. PubMed
  • Anderson KS, Gerber JE, D'Souza G, Pai SI, Cheng JN, Alam R, Kesiraju S, Chowell D, Gross ND, Haddad R, Gillison ML, Posner M. Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncol 2015; 51:751-8. PubMed
  • Ahn J, Bishop JA, Akpeng B, Pai SI, Best SR. Xenograft model for therapeutic drug testing in recurrent respiratory papillomatosis. Ann. Otol. Rhinol. Laryngol. 2015; 124:110-5. PubMed
  • Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB. Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS ONE 2015; 10:e116389. PubMed
  • Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE. In-situ tumor vaccination: Bringing the fight to the tumor. Hum Vaccin Immunother 2015; 11:1901-9. PubMed
Hide